Immunoglobulin Fusion Protein Market Report 2026

The immunoglobulin fusion protein market size has grown rapidly in recent years. It will grow from $46.05 billion in 2025 to $52.44 billion in 2026 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to biologic drug innovation, autoimmune disease burden, monoclonal antibody success, hospital biologics adoption, chronic disease management.

The immunoglobulin fusion protein market size is expected to see rapid growth in the next few years. It will grow to $87.21 billion in 2030 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to precision biologics development, rare disease drug pipelines, biosimilar competition, advanced protein engineering, long-acting therapy demand. Major trends in the forecast period include growing development of long-acting biologics, increased use of fc fusion technologies, expansion of autoimmune and rare disease applications, improved drug stability and half-life engineering, rising investment in protein engineering platforms.

The rising prevalence of autoimmune disorders is expected to drive growth in the immunoglobulin fusion protein market in the coming years. Autoimmune disorders are conditions in which the immune system mistakenly attacks healthy cells and tissues. This increase is primarily due to a combination of genetic predisposition and environmental factors, where inherited genes make individuals more susceptible and triggers such as infections or lifestyle contribute to disease development. Immunoglobulin fusion proteins help manage autoimmune disorders by modulating the immune response, reducing inflammation, and preventing the immune system from attacking the body’s own tissues. For example, according to Arthritis Australia in February 2024, an estimated 562,378 people in Australia will have rheumatoid arthritis (RA) in 2025, representing 14% of the total arthritis population. By 2040, this number is projected to rise by 33% to 748,721, an increase of 186,343 people compared to 2025. Therefore, the increasing prevalence of autoimmune disorders is driving growth in the immunoglobulin fusion protein market.

Leading companies in the immunoglobulin fusion protein market are conducting clinical trials to develop innovative products such as bispecific antibody fusion proteins, designed to enhance therapeutic efficacy and target multiple disease pathways. A bispecific antibody fusion protein is a genetically engineered molecule that can simultaneously bind two different targets, enhancing targeted therapy by bringing immune cells closer to tumor cells or blocking multiple disease pathways at once. For instance, in February 2025, Innovent Biologics, Inc., a China-based biotechnology company, received its second Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for IBI343, a bispecific antibody fusion protein targeting advanced solid tumors. IBI343 is designed to simultaneously engage tumor-associated antigens and immune effector cells, enhancing the precision and potency of anti-tumor immune responses. This designation is expected to accelerate the clinical development and regulatory review of IBI343, highlighting its potential to address significant unmet medical needs in oncology.

In April 2023, Yuhan Corporation, a South Korea-based pharmaceutical company, acquired Progen Inc. for an undisclosed amount. The acquisition aims to strengthen Yuhan’s capabilities in developing multi-target antibody therapeutics and enhance both domestic and international partnerships through the establishment of an Open Innovation Center with Progen. Progen Inc. is a South Korea-based biotechnology company specializing in immunoglobulin fusion protein development.

Major companies operating in the immunoglobulin fusion protein market are Amgen Inc., Pfizer Inc., Swedish Orphan Biovitrum AB (Sobi), Regeneron Pharmaceuticals Inc., Sanofi S.A., AbbVie Inc., Bristol-Myers Squibb Company, Roche Holding AG, Genentech Inc., UCB S.A., AstraZeneca PLC, CSL Behring, Takeda Pharmaceutical Company Limited, Novartis AG, Merck & Co. Inc., Biogen Inc., Horizon Therapeutics (Amgen subsidiary), Kyowa Kirin Co. Ltd., Ultragenyx Pharmaceutical Inc., Apellis Pharmaceuticals Inc., Alexion Pharmaceuticals (AstraZeneca subsidiary), Argenx SE, HanAll Biopharma Co. Ltd., Innovent Biologics Inc., 3SBio Inc.

North America was the largest region in the immunoglobulin fusion proteins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin fusion protein market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunoglobulin fusion protein market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created notable challenges in the immunoglobulin fusion protein market by increasing the cost of imported biologic raw materials, cell culture media, purification resins, and cold-chain packaging required for these complex therapies. Intravenous and subcutaneous fusion protein formulations used in autoimmune diseases, diabetes, and hemophilia are most affected, particularly in North America and Europe, where reliance on cross-border biopharmaceutical supply chains is high. Hospitals, research institutes, and specialty clinics face rising procurement and storage costs. However, tariffs are encouraging investment in domestic biologics manufacturing and localized antibody production facilities, which is strengthening long-term supply security and innovation.

The immunoglobulin fusion protein market research report is one of a series of new reports that provides immunoglobulin fusion protein market statistics, including immunoglobulin fusion protein industry global market size, regional shares, competitors with a immunoglobulin fusion protein market share, detailed immunoglobulin fusion protein market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin fusion protein industry. This immunoglobulin fusion protein market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An immunoglobulin fusion protein is a biologically engineered molecule formed by combining the functional domain of a target protein or peptide with the constant region of an immunoglobulin (antibody). This fusion increases the stability, half-life, and solubility of the target protein and can enhance its therapeutic effectiveness by utilizing the immune system’s natural mechanisms.

The main types of immunoglobulin fusion proteins include monoclonal antibodies, polyclonal antibodies, bispecific antibodies, and recombinant antibodies. Monoclonal antibodies are lab-designed proteins that specifically target and neutralize particular pathogens by mimicking the body’s immune response. Drug classes include immunosuppressive and immunostimulatory agents. These proteins are administered via intravenous, subcutaneous, or intramuscular injection and are applied in treating conditions such as autoimmune diseases, eye disorders, diabetes, and hemophilia. Primary end users include hospitals, clinics, and research institutes.

The immunoglobulin fusion protein market consists of sales of etanercept, abatacept, aflibercept, alefacept, and rilonacept. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.